Effect of magnesium on cognition after aneurysmal subarachnoid haemorrhage in a randomized trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

After aSAH, many patients have cognitive problems that may not translate into handicap.

Who Took Part

The study group was 209 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Three months after aSAH patients underwent a neuropsychological examination (NPE) consisting of six neuropsychological tests or a brief cognitive assessment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Poisson and linear regression analyses were used to analyse the effect of magnesium on cognition.

What Was Measured

The subject headings attached to it are Cognition, Cognition Disorders, Magnesium, Neuropsychological Tests and Subarachnoid Hemorrhage.

Author keywords: aneurysm, intervention and subarachnoid haemorrhage.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 209 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (European journal of neurology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.